Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis
Year: 2019
Type: review
Abstract: The Accelerating Medicines Partnership (AMP) Lupus Network was established as a partnership between the National Institutes of Health, pharmaceutical companies, nonprofit stakeholders, and lupus investigators across multiple academic centers to apply high-throughput technologies to the analysis of renal tissue, urine, and blood from patients with lupus nephritis (LN). The AMP network provides publicly accessible data to the community with the goal of generating new scientific hypotheses and improving diagnostic and therapeutic tools so as to improve disease outcomes. We present here a description of the structure of the AMP Lupus Network and a summary of the preliminary results from the phase 1 studies. The successful completion of phase 1 sets the stage for analysis of a large cohort of LN samples in phase 2 and provides a model for establishing similar discovery cohorts.
Source: Arthritis Care & Research
DOI: 10.1002/acr.24066
Institutions: Broad Institute, Albert Einstein College of Medicine, Montefiore Medical Center, University of Michigan, Brigham and Women's Hospital, Harvard University, Oklahoma Medical Research Foundation, New York University, Johns Hopkins University, University of California, San Francisco, Northwell Health, Feinstein Institute for Medical Research
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Arthritis Foundation, Lupus Foundation of America, Bristol-Myers Squibb, Pfizer, Sanofi, Brigham and Women's Hospital, Rheumatology Research Foundation, AbbVie, Texas Tech University, Johns Hopkins University, University of Oklahoma, University of Rochester, University of Cincinnati, University of South Carolina, Temple University, Lupus Research Alliance, Cedars-Sinai Medical Center, Broad Institute, Northwell Health, National Institutes of Health, University of California, Los Angeles, University of California, San Diego, University of California, San Francisco, Takeda Pharmaceuticals International, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Janssen Pharmaceuticals
Awards: Accelerating Medicines Partnership in RA and Lupus: Network Sites (UH2/UH3), RA-SLE Molecular Deconstruction Leadership Center, UPITT Rheumatoid Arthritis Combined Center (UPITT RACC), Evolving Adaptive and Effector Mechanisms from Pre-RA Through Established Disease, Multi-Ethnic Translational Research Optimization (METRO) Lupus Consortium, G3600930533, Stanford Technology Accelerating Medicines Partnership Center, Molecular and Cellular Dissection of Early Rheumatoid Arthritis, Molecular Pathways in Treatment Response and Flare in RA, Hopkins Lupus Cohort, Cellular Dynamics at the Synovium-Bone interface in RA, PEARL: Pathway Exploration and Analysis in Renal Lupus, AMP RA/SLE Leadership Center
OpenAlex ID: W2972402989